Sembragiline

Drug Name: Sembragiline
Company: Evotec
Location: Germany
Website: http://www.evotec.com
Drug Type: Small Molecule
Conditions: ALS, Alzheimer’s disease
Mechanism Type: Anitoxidant
Mechanism: EV302 is an inhibitor of monoamine oxidase B, an enzyme that breaks down dopamine, and contributes to production of free radicals and oxidative stress conditions.
U.S. Status for ALS: Preclinical

References:
[1] Roche forced to concede another flop for Alzheimer’s program. Carroll, J. FierceBiotech, 1 Jul 2015. Accessed 11 Mar 2016 from http://www.fiercebiotech.com/story/roche-forced-concede-another-flop-alzheimers-program/2015-07-01.
[2] Evotec and Harvard Stem Cell Institute form CureMN collaboration to advance ALS research. Evotec, 12 Sep 2013. Accessed 9 Mar 2016 from https://www.evotec.com/article/en/Press-releases/Evotec-and-Harvard-Stem-Cell-Institute-form-CureMN-collaboration-to-advance-ALS-research/2435.
[3]

Last updated March 9th, 2016

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail